Galenica

M&A underpins FY25 Guidance upgrade, but Muted Investor Day raises skepticism

30/10/25 -"Galenica’s YTD 2025 sales reached CHF 2,999.7 million, growing by 4.7%. This growth was driven by strong tailwinds from prescription drugs, particularly GLP-1 products. The completion of the ..."

PDF page sample
Pages
48
Language
English
Published on
30/10/25
Download
You may also be interested by these reports :
30/10/25
Galenica’s YTD 2025 sales reached CHF 2,999.7 million, growing by 4.7%. This growth was driven by strong tailwinds from prescription drugs, ...
29/10/25
3Q25: Adj. EBITDA exceeded expectations – Confirmed FY25E guidance
16/10/25
Travis Perkins’ Q3 FY25 results showed 1.8% yoy lfl sales growth, slightly beating market expectations, driven by gains in merchanting and ...
16/10/25
3Q25: Sales slightly missed expectations – Full year guidance confirmed

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO